| Literature DB >> 28823558 |
Luisa Cimmino1, Igor Dolgalev2, Yubao Wang3, Akihide Yoshimi4, Gaëlle H Martin5, Jingjing Wang6, Victor Ng5, Bo Xia5, Matthew T Witkowski6, Marisa Mitchell-Flack6, Isabella Grillo6, Sofia Bakogianni6, Delphine Ndiaye-Lobry6, Miguel Torres Martín7, Maria Guillamot6, Robert S Banh3, Mingjiang Xu8, Maria E Figueroa7, Ross A Dickins9, Omar Abdel-Wahab4, Christopher Y Park5, Aristotelis Tsirigos2, Benjamin G Neel10, Iannis Aifantis11.
Abstract
Loss-of-function mutations in TET2 occur frequently in patients with clonal hematopoiesis, myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML) and are associated with a DNA hypermethylation phenotype. To determine the role of TET2 deficiency in leukemia stem cell maintenance, we generated a reversible transgenic RNAi mouse to model restoration of endogenous Tet2 expression. Tet2 restoration reverses aberrant hematopoietic stem and progenitor cell (HSPC) self-renewal in vitro and in vivo. Treatment with vitamin C, a co-factor of Fe2+ and α-KG-dependent dioxygenases, mimics TET2 restoration by enhancing 5-hydroxymethylcytosine formation in Tet2-deficient mouse HSPCs and suppresses human leukemic colony formation and leukemia progression of primary human leukemia PDXs. Vitamin C also drives DNA hypomethylation and expression of a TET2-dependent gene signature in human leukemia cell lines. Furthermore, TET-mediated DNA oxidation induced by vitamin C treatment in leukemia cells enhances their sensitivity to PARP inhibition and could provide a safe and effective combination strategy to selectively target TET deficiency in cancer. PAPERCLIP.Entities:
Keywords: DNA demethylation; DNA oxidation; HSCs; PARP inhibitor; TET2; hydroxymethylcytosine; leukemia; reversible RNAi; self-renewal; vitamin C
Mesh:
Substances:
Year: 2017 PMID: 28823558 PMCID: PMC5755977 DOI: 10.1016/j.cell.2017.07.032
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582